Relevant bibliographies by topics / Overall survival (OS) / Journal articles
To see the other types of publications on this topic, follow the link: Overall survival (OS).

Journal articles on the topic 'Overall survival (OS)'

Author: Grafiati
Published: 4 June 2025
Last updated: 8 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Overall survival (OS).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Burke, Harry B. "Overall Survival vs Disease-Specific Survival." JAMA Oncology 4, no. 4 (2018): 586. http://dx.doi.org/10.1001/jamaoncol.2016.6786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mailankody, Sham, and Vinay Prasad. "Overall Survival vs Disease-Specific Survival—Reply." JAMA Oncology 4, no. 4 (2018): 586. http://dx.doi.org/10.1001/jamaoncol.2017.3865.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tuma, Rabiya S. "Vemurafenib ‘Dramatically’ Extends Overall Survival." Oncology Times 34, no. 6 (2012): 28. http://dx.doi.org/10.1097/01.cot.0000413562.37895.e5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Burki, Talha Khan. "Blinatumomab significantly improves overall survival." Lancet Oncology 18, no. 4 (2017): e203. http://dx.doi.org/10.1016/s1470-2045(17)30183-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Li, T., M. Thompson, and D. Tran. "Metastatic-Free Survival And Overall Survival In Prostate Cancer." Value in Health 18, no. 3 (2015): A14. http://dx.doi.org/10.1016/j.jval.2015.03.088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Krstevska Balkanov, Svetlana, Sanja Trajkova, Sonja Genadieva Stavric, et al. "Myeloma multiplex treatment and overall survival." Macedonian Pharmaceutical Bulletin 67, no. 1 (2021): 79–90. http://dx.doi.org/10.33320/10.33320/maced.pharm.bull.2021.67.01.008.

Full text
Abstract:
The Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. This retrospective-prospective study was conducted at the University Clinic for Hematology in Skopje, North Macedonia, in the period between January 2009 and December 2019. Patients younger than 65 years, without comorbidities, fit for autologous peripheral blood stem cell transplantation (PBSCT), were treated with Cyclophosphamide-Thalidomide-Dexamethasone (CyThalDex) protocol divided into two daily doses which were maintained until complete remission. Patients over 65 years of age, unfit for more aggressive treatment options like peripheral blood stem cells (PBSCT) with comorbidities and renal failure, were treated with Melphalan-Prednisone-Thalidomide (MPT) protocol. The third group of patients was treated without new immunomodulators such as thalidomide, but instead a salvage therapy was given consisted of chemotherapy and corticosteroids. The use of thalidomide can lead to more undesirable effects such as deep vein thrombosis and renal neuropathy. The results obtained in our study showed no high percentage of these effects. However, a better survival rate was registered along with a longer period without progression of the underlying disease (PFS). Moreover, a higher percentage of complete remission (CR) was achieved and a very good partial response (VGPR) in general. Myeloma multiplex is still incurable disease with pattern of regression and remission followed by multiple relapses rising from the residual myeloma cells, but in the future still many unsolved questions has to be answered. Keywords: myeloma multiplex, autologous stem cell transplantation, thalidomide
APA, Harvard, Vancouver, ISO, and other styles
7

Amelot, Aymeric, Joseph Cristini, Céline Salaud, et al. "Overall Survival in Spine Myeloma Metastases." SPINE 42, no. 6 (2017): 400–406. http://dx.doi.org/10.1097/brs.0000000000001766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Goodman, Alice. "Azacitidine Prolongs Overall Survival in MDS." Oncology Times 30 (February 2008): 3–4. http://dx.doi.org/10.1097/01.cot.0000312305.78348.9c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Goodman, Alice. "Azacitidine prolongs overall survival in MDS." Oncology Times UK 5, no. 2 (2008): 14. http://dx.doi.org/10.1097/01434893-200802000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

EVANS, JEFF. "Prostate Cancer Vaccine Increased Overall Survival." Clinical Psychiatry News 33, no. 7 (2005): 61. http://dx.doi.org/10.1016/s0270-6644(05)70550-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Sidaway, Peter. "Addition of capecitabine prolongs overall survival." Nature Reviews Clinical Oncology 14, no. 4 (2017): 198. http://dx.doi.org/10.1038/nrclinonc.2017.21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Driscoll, James J., and Oliver Rixe. "Overall Survival: Still the Gold Standard." Cancer Journal 15, no. 5 (2009): 401–5. http://dx.doi.org/10.1097/ppo.0b013e3181bdc2e0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Loprinzi, Charles L. "Recombinant human erythropoietin and overall survival." Current Oncology Reports 7, no. 4 (2005): 269–70. http://dx.doi.org/10.1007/s11912-005-0049-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Printz, Carrie. "Pancreatic cancer drug improves overall survival." Cancer 120, no. 4 (2014): 459. http://dx.doi.org/10.1002/cncr.28582.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Feinberg, Bruce, and Iris Feinberg. "Overall survival of the medical oncologist." Cancer 82, S10 (1998): 2047–56. http://dx.doi.org/10.1002/(sici)1097-0142(19980515)82:10+<2047::aid-cncr13>3.0.co;2-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

RADES, DIRK, LIESA DZIGGEL, THEO VENINGA, AMIRA BAJROVIC, and STEVEN E. SCHILD. "Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer." Anticancer Research 36, no. 9 (2016): 4817–20. http://dx.doi.org/10.21873/anticanres.11042.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Fan, Yiwei, and Guosheng Yin. "Concordance index: Surrogacy of progression-free survival for overall survival." Contemporary Clinical Trials 104 (May 2021): 106353. http://dx.doi.org/10.1016/j.cct.2021.106353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Felizzi, F., I. Bennett, M. Pletscher, P. Thuresson, N. Paracha, and J. Ray. "PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL." Value in Health 21 (October 2018): S382—S383. http://dx.doi.org/10.1016/j.jval.2018.09.2275.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Ouwens, M. J., and G. Bergman. "PRM12 Joint Estimation of Progression Free Survival and Overall Survival." Value in Health 15, no. 7 (2012): A462. http://dx.doi.org/10.1016/j.jval.2012.08.1476.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Buyukhatipoglu, Hakan, Taner Babacan, Neyran Kertmen, et al. "Tumor locations significantly affect disease free survival and overall survival." Journal of Clinical Oncology 33, no. 15_suppl (2015): e12590-e12590. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e12590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Baculea, S., S. Horsburgh, S. Chadda, L. Nelson, and C. LeReun. "PF389 PROGRESSION-FREE SURVIVAL PREDICTS OVERALL SURVIVAL IN FRONTLINE CLL." HemaSphere 3, S1 (2019): 146–47. http://dx.doi.org/10.1097/01.hs9.0000559768.28570.89.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Escudier, Bernard. "Progression-free survival as a surrogate marker of overall survival." Cancer 117, no. 12 (2011): 2586–87. http://dx.doi.org/10.1002/cncr.25955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Aissaoui, A., A. Bin Sawad, F. Turkistani, and N. Aissaoui. "Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials." Value in Health 19, no. 7 (2016): A717. http://dx.doi.org/10.1016/j.jval.2016.09.2124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Provencio, M., R. Serna, E. Nadal, et al. "PL03.12 Progression Free Survival and Overall Survival in NADIM II Study." Journal of Thoracic Oncology 17, no. 9 (2022): S2—S3. http://dx.doi.org/10.1016/j.jtho.2022.07.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Jansen, J. P., and T. Trikalinos. "Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival." Value in Health 16, no. 7 (2013): A617. http://dx.doi.org/10.1016/j.jval.2013.08.1791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Hernandez-Villafuerte, Karla, Alastair Fischer, Nicholas Latimer, and Chris Henshall. "VP87 Extrapolation From Progression Free Survival To Overall Survival In Oncology." International Journal of Technology Assessment in Health Care 33, S1 (2017): 188–89. http://dx.doi.org/10.1017/s0266462317003543.

Full text
Abstract:
INTRODUCTION:The outcomes from clinical and other healthcare trials of most interest to patients and health systems are usually increases in the quality and length of life (overall survival (OS)). This poses a problem, because complete knowledge on the true increase in OS is not available until the last person in the trial dies. However, if OS is sufficiently correlated with a surrogate endpoint that is observable within the trial period or soon after the treatment has finished, this can be used to estimate OS, without much error. The most widely-used surrogate endpoint in oncology is progression-free survival (PFS). We aim at (i) analyzing the methods used to extrapolate from PFS to OS in the field of oncology; (ii) identifying whether a clear guidance exists in the literature about what is considered to be ‘best practice’ in extrapolation from PFS to OS; (iii) determining the key limitations, weaknesses and gaps in the current literature and method used to test PFS surrogacy.METHODS:We extend the literature review carried out previously (1), we interview experts from regulatory and reimbursement bodies, and we explore academic research into the methodology of surrogacy and the need for better reporting of surrogacy papers.RESULTS:A number of factors affect the relationship between PFS and OS. Therefore, there is no unique correct answer for the question of whether PFS is an appropriate surrogate for OS in oncology. Many of these factors are related to the length and characteristics of post-progression survival (PPS).CONCLUSIONS:Any consideration of evidence relating to PFS should consider both tumour type and other factors, particularly those related to PPS. Protocols of future follow-up of clinical trial patients should specify procedures for gathering information about the effect of post-progression management of the disease. This should allow stronger conclusions to be extracted from statistical analyses. Improved reporting standards will aid in achieving this goal. In addition, it is very likely that increasing the use of IPD will result in greater precision in estimating the benefits of worthwhile drugs.
APA, Harvard, Vancouver, ISO, and other styles
27

Takei, Hisashi, Hiromi Koiso, Morio Matsumoto, et al. "Initial extramedullary myeloma impacts overall survival via affecting post progression survival." Clinical Lymphoma Myeloma and Leukemia 19, no. 10 (2019): e194-e195. http://dx.doi.org/10.1016/j.clml.2019.09.324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Dittrich, C. "Response, disease-free survival, and overall survival: What matters for whom?" European Surgery 42, no. 1 (2010): 5–7. http://dx.doi.org/10.1007/s10353-010-0520-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Wen-zhuo, He, and Xia Liang-ping. "RE: Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival." Journal of the National Cancer Institute 108, no. 1 (2015): djv311. http://dx.doi.org/10.1093/jnci/djv311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Fuerst, Mark L. "Pembrolizumab for Overall Survival in Hepatocellular Carcinoma." Oncology Times 43, no. 4 (2021): 27. http://dx.doi.org/10.1097/01.cot.0000735072.57343.f6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

DiGiulio, Sarah. "Eribulin Improves Overall Survival for Liposarcoma, Leiomyosarcoma." Oncology Times 38, no. 9 (2016): 30. http://dx.doi.org/10.1097/01.cot.0000483224.05770.22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Fuerst, Mark L. "Maintenance Therapy Improves Overall Survival in AML." Oncology Times 42 (January 2020): 8. http://dx.doi.org/10.1097/01.cot.0000653336.35007.90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Edwards, Beatrice J., Xiaotao Zhang, Ming Sun, et al. "Overall survival in older patients with cancer." BMJ Supportive & Palliative Care 10, no. 1 (2018): 25–35. http://dx.doi.org/10.1136/bmjspcare-2018-001516.

Full text
Abstract:
ObjectivesA growing number of patients with cancer are older adults. We sought to identify the predictors for overall survival (OS) in older adults with solid tumour and haematological malignancies between January 2013 and December 2016.MethodsRetrospective cohort study. A comprehensive geriatric assessment was performed, with a median follow-up of 12.8 months. Analysis: univariate and multivariate Cox proportional hazards regression analysis.ResultsIn this study, among the 455 patients with last follow-up date or date of death, 152 (33.4%) died during the follow-up. The median follow-up is 12.8 months (range 0.2–51.1 months) and the median OS is 20.5 months (range 0.3–44.5 months). Among all older patients with cancer, predictors of OS included male gender, cancer stage, malnutrition, history of smoking, heavy alcohol use, frailty, weight loss, major depression, low body weight and nursing home residence. Traditional performance scores (Eastern Cooperative Oncology Group (ECOG) and Karnofsky Performance Scale (KPS)) were predictors of OS. Independent predictors included age &gt;85 years and haematological malignancies. Among solid tumours (n=311) in addition to the above predictors, comorbidity, gait speed and vitamin D deficiency were associated with OS.ConclusionsWe identified specific geriatric factors associated with OS in older patients with cancer, and comparable in predictive ability to traditional performance scores such as KPS and ECOG. Prospective studies will be necessary to confirm our findings.
APA, Harvard, Vancouver, ISO, and other styles
34

Rizzitelli, Alexandra, Nicolas R. Smoll, Michael P. Chae, Warren M. Rozen, and David J. Hunter-Smith. "Incidence and Overall Survival of Malignant Ameloblastoma." PLOS ONE 10, no. 2 (2015): e0117789. http://dx.doi.org/10.1371/journal.pone.0117789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Warwick, D., and M. Freeman. "Overall survival rate is most important measure." BMJ 311, no. 7004 (1995): 572. http://dx.doi.org/10.1136/bmj.311.7004.572a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Trichopoulou, A., A. Kouris-Blazos, M. L. Wahlqvist, et al. "Diet and overall survival in elderly people." BMJ 311, no. 7018 (1995): 1457–60. http://dx.doi.org/10.1136/bmj.311.7018.1457.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Vinall, M., and S. Stintzing. "FOLFIRI Plus Cetuximab Prolongs Overall mCRC Survival." MD Conference Express 13, no. 6 (2013): 17–18. http://dx.doi.org/10.1177/155989771306012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

&NA;. "Lenalidomide improves overall survival in multiple myeloma." Oncology Times UK 8, no. 6 (2011): 14. http://dx.doi.org/10.1097/01.otu.0000399064.88986.fd.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

FREEMAN, SARA. "Geriatric evaluation predicts overall survival in AML." Community Oncology 8, no. 12 (2011): 555–56. http://dx.doi.org/10.1016/s1548-5315(12)70120-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

D'Andrea, Giancarlo, Lucia Palombi, Giuseppe Minniti, Alessandro Pesce, and Paolo Marchetti. "Brain Metastases: Surgical Treatment and Overall Survival." World Neurosurgery 97 (January 2017): 169–77. http://dx.doi.org/10.1016/j.wneu.2016.09.054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Mayor, Susan. "Immunotherapy improves overall survival in pancreatic cancer." Lancet Oncology 16, no. 2 (2015): e58. http://dx.doi.org/10.1016/s1470-2045(15)70017-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Kehoe, Sean. "Olaparib and ovarian cancer—overall survival outcomes." Lancet Oncology 17, no. 11 (2016): 1474–75. http://dx.doi.org/10.1016/s1470-2045(16)30433-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Gourd, Elizabeth. "Sarcopenia and adiposity linked to overall survival." Lancet Oncology 19, no. 5 (2018): e239. http://dx.doi.org/10.1016/s1470-2045(18)30284-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Gourd, Elizabeth. "Overall survival with osimertinib in untreated NSCLC." Lancet Oncology 21, no. 1 (2020): e15. http://dx.doi.org/10.1016/s1470-2045(19)30778-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Shah, Chirag, and Frank A. Vicini. "Regional Nodal Irradiation: Moving Beyond Overall Survival." International Journal of Radiation Oncology*Biology*Physics 94, no. 1 (2016): 208–9. http://dx.doi.org/10.1016/j.ijrobp.2015.09.031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Lok, Anne, jean-Come Meniane, Clarisse Joachim, et al. "Myeloma in Martinique; Characteristics and Overall Survival." Blood 124, no. 21 (2014): 5772. http://dx.doi.org/10.1182/blood.v124.21.5772.5772.

Full text
Abstract:
Abstract Introduction African Americans (AA) are twice as likely to be diagnosed with multiple myeloma (MM) as Caucasian Americans (CA). Differences in overall survival have also been shown between those two populations with no consistent explanation with regard to social status or genetic profile given by gene expression profiling. In Martinique, where most of the population has African or French Caribbean ethnic origin with similar increased incidence in MM, we lack data about disease characteristics and survival as compared to French Caucasian patients. Material and methods The aim of this single center retrospective study was to evaluate characteristics, progression free and overall survival of this population. We analyzed 54 MM elderly patients consecutively treated in Fort de France Hematology department from March 2007 to March 2012. All patients received first line treatment with melphalan 0.2 mg/kg/d, prednisone 2 mg/kg/d and thalidomide 400 mg/d every 6 weeks according to French IFM guidelines. Disease characteristics and survival data were analyzed and compared to French Caucasian elderly MM patients included in first line IFM published trials. Results Population had a median age of 80 years (66 to 93). Concerning prognostic markers, International Scoring System (ISS) was of 3 (high) in 52% of patients and cytogenetic analysis showed rearrangements with translocation 14q32 in 22% with 7% of t(4;14). When considering deletion 13q, it was found in 41% and deletion 17p in 6%. With a median follow up of 35 months, survival features showed median overall survival (OS) of 48.6 months and progression free survival (PFS) of 28.9 months. Discussion Compared to French Caucasian patients, our series showed that Martinique’s population was older and presented more aggressive disease based on ISS. Moreover, almost half patients presented with MDRD clearance lower than 60ml/min which conferred higher B2m and worse prognosis. We also confirmed results recently published by Weiss and all who described lower rate of IgH translocation in African American population with MM. Despite higher median age and ISS, median overall survival of our population was unexpectedly similar to French published studies with IFM 99 06 trial showing median OS and PFS in MPT arm of 51.6 and 27.5 months respectively. In IFM 01/01 trial where patients were aged more than 75 with lower doses of melphalan and thalidomide, survival data showed median OS of 44 months and median PFS of 24.1 months. In meta analysis published by European Myeloma Network, median OS was even lower with 39.3 months. Our data tend to show that French Caribbean patients with first line MM treated in Martinique appear to have similar overall survival as compared to French Caucasian patients despite higher median age and more adverse prognostic features which has not been reported so far. We plan to confirm those data with new analysis with longer median follow up and extensive clinical and biological disease characteristics evaluation. Disclosures Moreau: celgene: Consultancy.
APA, Harvard, Vancouver, ISO, and other styles
47

Shayegan, Bobby. "Mitigating pelvic recurrence and improving overall survival." Canadian Urological Association Journal 10, no. 3-4 (2016): 95. http://dx.doi.org/10.5489/cuaj.3772.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Song, Xue, Zhongyun Zhao, Beth Barber, Amanda M. Farr, Boris Ivanov, and Marilyn Novich. "Overall survival in patients with metastatic melanoma." Current Medical Research and Opinion 31, no. 5 (2015): 987–91. http://dx.doi.org/10.1185/03007995.2015.1021904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Anaya, D. A., G. Lahat, J. Liu, et al. "Multifocality and overall survival in retroperitoneal sarcoma." Journal of Clinical Oncology 26, no. 15_suppl (2008): 10579. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.10579.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Groves-Kirkby, Nick. "Renal preservation improves cardiac and overall survival." Nature Reviews Urology 7, no. 5 (2010): 237. http://dx.doi.org/10.1038/nrurol.2010.52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Overall survival (OS)' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography